Effective Treatment of Coprophagia in a Patient with Schizophrenia with the Novel Atypical Antipsychotic Drug Perospirone

Here we report on a patient with schizophrenia who suffered from medication-refractory coprophagia. Although there were few cases in which psychotropic medication was effective against coprophagia, we encountered a patient with schizophrenia in whom coprophagia rapidly disappeared after treatment with perospirone, a novel atypical antipsychotic drug of the serotonin-dopamine antagonist (SDA) type. Perospirone has a uniquely high affinity for serotonin-1A receptors, and it could be speculated that perospirone, as a serotonin-1A receptor agonist combined with SDA, may have greater efficacy for treatment-refractory symptoms of schizophrenia. Thus, perospirone is an agent with possible efficacy for medication-refractory schizophrenia.

References

• 1 Bantick R A, Deakin J FW, Grasby P M. The 5-HT_1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?.  J Psychopharmacol. 2001;  15 37-46
• 2 Chaturvedi S K. Coprophagia in a schizophrenic patient: case report.  Psychopathology. 1988;  21 31-33
• 3 Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M. Binding profile of SM-9018, a novel antipsychotic candidate.  Jpn J Pharmacol. 1990;  54 478-481